Argus Research raised Biogen (NASDAQ:BIIB) price target from $320 to $350

By / / Argus, Biogen

Argus Research analyst Jasper Hellweg maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $320 to $350.

Scroll to Top